ATR-Mediated Global Fork Slowing and Reversal Assist Fork Traverse and Prevent Chromosomal Breakage at DNA Interstrand Cross-Links by Mutreja, Karun et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
ATR-Mediated Global Fork Slowing and Reversal Assist Fork Traverse and
Prevent Chromosomal Breakage at DNA Interstrand Cross-Links
Mutreja, Karun; Krietsch, Jana; Hess, Jeannine; Ursich, Sebastian; Berti, Matteo; Roessler, Fabienne
K; Zellweger, Ralph; Patra, Malay; Gasser, Gilles; Lopes, Massimo
Abstract: Interstrand cross-links (ICLs) are toxic DNA lesions interfering with DNA metabolism that
are induced by widely used anticancer drugs. They have long been considered absolute roadblocks for
replication forks, implicating complex DNA repair processes at stalled or converging replication forks.
Recent evidence challenged this view, proposing that single forks traverse ICLs by yet elusive mechanisms.
Combining ICL immunolabeling and single-molecule approaches in human cells, we now show that ICL
induction leads to global replication fork slowing, involving forks not directly challenged by ICLs. Active
fork slowing is linked to rapid recruitment of RAD51 to replicating chromatin and to RAD51/ZRANB3-
mediated fork reversal. This global modulation of fork speed and architecture requires ATR activation,
promotes single-fork ICL traverse-here, directly visualized by electron microscopy-and prevents chromo-
somal breakage by untimely ICL processing. We propose that global fork slowing by remodeling provides
more time for template repair and promotes bypass of residual lesions, limiting fork-associated processing.
DOI: https://doi.org/10.1016/j.celrep.2018.08.019
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-153607
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Mutreja, Karun; Krietsch, Jana; Hess, Jeannine; Ursich, Sebastian; Berti, Matteo; Roessler, Fabienne
K; Zellweger, Ralph; Patra, Malay; Gasser, Gilles; Lopes, Massimo (2018). ATR-Mediated Global Fork
Slowing and Reversal Assist Fork Traverse and Prevent Chromosomal Breakage at DNA Interstrand
Cross-Links. Cell Reports, 24(10):2629-2642.e5.
DOI: https://doi.org/10.1016/j.celrep.2018.08.019
Article
ATR-Mediated Global Fork Slowing and Reversal
Assist Fork Traverse and Prevent Chromosomal
Breakage at DNA Interstrand Cross-Links
Graphical Abstract
Highlights
d Fork slowing and reversal are also observed at forks not
directly challenged by ICLs
d Fork reversal assists ICL traverse and limits DSBs associated
with ICL unhooking
d ICL traverse can be directly visualized in human cells by
electron microscopy
d ATRmediates global fork slowing and reversal upon different
genotoxic treatments
Authors
Karun Mutreja, Jana Krietsch,
Jeannine Hess, ..., Malay Patra,
Gilles Gasser, Massimo Lopes
Correspondence
lopes@imcr.uzh.ch
In Brief
Replication-coupled repair of DNA
interstrand cross-links (ICLs) promotes
resistance to chemotherapeutic
treatments. Visualizing individual lesions
and replication intermediates, Mutreja
et al. report that forks slow down and
reverse both at ICLs and away from
lesions. This ATR-mediated response
assists lesion bypass during replication
and limits chromosomal breakage by
fork-associated processing.
Mutreja et al., 2018, Cell Reports 24, 2629–2642
September 4, 2018 ª 2018 The Authors.
https://doi.org/10.1016/j.celrep.2018.08.019
Cell Reports
Article
ATR-Mediated Global Fork Slowing and Reversal
Assist Fork Traverse and Prevent Chromosomal
Breakage at DNA Interstrand Cross-Links
Karun Mutreja,1 Jana Krietsch,1 Jeannine Hess,3,4 Sebastian Ursich,1 Matteo Berti,1 Fabienne K. Roessler,1,2
Ralph Zellweger,1 Malay Patra,3 Gilles Gasser,3,5 and Massimo Lopes1,6,*
1Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
2Center for Microscopy and Image Analysis, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
3Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
4Present address: Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
5Present address: Chimie ParisTech, PSL University, Laboratory for Inorganic Chemical Biology, F-75005 Paris, France
6Lead Contact
*Correspondence: lopes@imcr.uzh.ch
https://doi.org/10.1016/j.celrep.2018.08.019
SUMMARY
Interstrand cross-links (ICLs) are toxic DNA lesions
interfering with DNA metabolism that are induced
by widely used anticancer drugs. They have long
been considered absolute roadblocks for replication
forks, implicating complex DNA repair processes at
stalled or converging replication forks. Recent evi-
dence challenged this view, proposing that single
forks traverse ICLs by yet elusive mechanisms.
Combining ICL immunolabeling and single-molecule
approaches in human cells, we now show that ICL
induction leads to global replication fork slowing,
involving forks not directly challenged by ICLs.
Active fork slowing is linked to rapid recruitment of
RAD51 to replicating chromatin and to RAD51/
ZRANB3-mediated fork reversal. This global modula-
tion of fork speed and architecture requires ATR acti-
vation, promotes single-fork ICL traverse—here,
directly visualized by electron microscopy—and pre-
vents chromosomal breakage by untimely ICL pro-
cessing. We propose that global fork slowing by
remodeling provides more time for template repair
and promotes bypass of residual lesions, limiting
fork-associated processing.
INTRODUCTION
Interstrand cross-links (ICLs) are DNA lesions that prevent DNA
strand separation, thereby interfering with crucial DNA transac-
tions for cellular proliferation, such as replication and transcrip-
tion. In light of this toxicity, ICL-inducing agents, such as
cisplatin and nitrogen mustards, are among the most widely
used compounds in cancer treatment (Deans and West, 2011).
Moreover, ICL can be endogenously induced by reactive alde-
hyde species arising as by-product of natural cellular meta-
bolism (Langevin et al., 2011). Repair of these lesions has been
thoroughly studied in recent years and may occur in a replica-
tion-dependent or -independent manner (Williams et al., 2013).
Several DNA repair pathways have been implicated in ICL
replication and repair. These mechanisms have received major
attention since the discovery that the human bonemarrow failure
syndrome Fanconi anemia (FA), also associated with cancer pre-
disposition, results from mutations in more than 20 independent
genes that play a common crucial role in ICL repair (Kottemann
and Smogorzewska, 2013). These include factors required to
incise the DNA backbone for ICL unhooking—such as SLX4
and XPF/ERCC1 (Klein Douwel et al., 2014)—homologous
recombination (HR) factors to repair associated double-
stranded breaks (DSBs)—such as RAD51, BRCA1/BRIP1,
BRCA2, and PALB2—and translesion polymerases to synthe-
size DNA opposite the unhooked ICL (Zhang and Walter,
2014). Many other FA factors regulate this pathway by associ-
ating in the so-called FA ‘‘core-complex,’’ which mediates ubiq-
uitination of FANCD2 and FANCI, a crucial regulatory event in
ICL replication and repair (Ceccaldi et al., 2016).
ICLs have long been seen as absolute roadblock for the repli-
cation forks; thus, most ICL repair transactions described above
have been suggested to occur at stalled forks (Zhang andWalter,
2014). Mechanisms and kinetics of these events have been stud-
ied in great detail in cell-free Xenopus egg extracts, using plas-
mids carrying a single synthetic ICL (Ra¨schle et al., 2008). These
studies have supported a model in which a first fork is stalled at
the ICL, but ICL processing and removal require a second
incoming fork and replisome disassembly (Long et al., 2014;
Zhang et al., 2015). An important implication of these studies is
that ICL unhooking, DSB formation, and HR-mediated repair
occur relatively late, once bulk DNA replication has been
achieved (Long et al., 2011). Recent studies in mammalian cells
have, however, challenged this model. A key ICL-repair factor
FANCD2 has been shown to associate with the replisome,
regulating unwinding by the replicative helicase (Lossaint et al.,
2013). Furthermore, key ubiquitin-regulated events that mediate
resistance to ICL-inducing agents—i.e., FANCD2 ubiquitina-
tion and recruitment of FAN1 nuclease—are not required
for ICL repair, but rather to regulate replication fork progression
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(Lachaud et al., 2016), suggesting that active regulation of DNA
synthesis may play a pivotal—albeit undefined—role in the
response to ICL-inducing agents. Moreover, single-molecule
studies in mammalian cells have surprisingly shown that—
despite some pausing—single forks can efficiently traverse
ICLs (Huang et al., 2013), challenging the fork convergence
model. ICL traverse was shown to depend on FANCM, a DNA
translocase that mediates replication fork remodeling in vitro
(Gari et al., 2008; Huang et al., 2013). However, mechanistic un-
derstanding of how template unwinding and fork restart are
achieved after fork stalling at ICLs is still very limited. ICL traverse
would in principle require de novo template unwinding beyond
the lesion—which challenges established dogmas of helicase
recruitment and regulation—and may require extensive remod-
eling of fork architecture and/or changes in replisome composi-
tion or function.
Recent direct visualization of replication fork architecture
in human cells has uncovered extensive remodeling of forks
into four-way junctions—a process known as replication fork
reversal—in response to different conditions of replication stress
(Berti and Vindigni, 2016; Neelsen and Lopes, 2015; Quinet et al.,
2017). Fork reversal was shown to prevent chromosomal
breakage upon different treatments and has emerged as a
reversible, genetically controlled transaction supporting genome
stability upon genotoxic treatments (Berti et al., 2013; Ray
Chaudhuri et al., 2012; Thangavel et al., 2015). The key recombi-
nase RAD51 as well as the DNA translocase ZRANB3 were
shown to drive replication fork reversal in vivo, thereby modu-
lating the rate of fork progression and error-free DNA damage
tolerance in human cells (Vujanovic et al., 2017; Zellweger
et al., 2015). Surprisingly, fork remodeling was found to be
largely independent from the type and the dose of the genotoxic
treatment (Zellweger et al., 2015), suggesting that it may repre-
sent a general cellular response, promoted and limited by spe-
cific signaling mechanisms.
Ataxia telangiectasia and Rad3-related (ATR) is the apical ki-
nase coordinating replication stress responses in human cells
(Saldivaret al., 2017). ATRand itskey targetCHK1 limit originfiring
during unperturbed S phase (Katsuno et al., 2009) and upon repli-
cation stress (Costanzo et al., 2003; Karnani and Dutta, 2011),
limiting exhaustionof nucleotides andof the single-strand binding
protein RPA, thereby preventing replication catastrophe (Toledo
et al., 2013). In both yeast and human cells, ATRmodulates origin
firing by limiting chromatin recruitment of the initiation factor
CDC45,whichalongwith activationof theDDK (CDC7) is essential
to fire replication origins. ATR inhibits CDC45 loading via phos-
phorylation of the replisome component Sld3/Treslin and of the
histone methyltransferase MLL (Guo et al., 2015; Liu et al., 2010;
Lopez-Mosqueda et al., 2010; Zegerman and Diffley, 2010).
Although numerous replisome components, accessory fac-
tors, and HR proteins have been identified as ATR targets (Ahl-
skog et al., 2016; Errico and Costanzo, 2012; Lossaint et al.,
2013; Murphy et al., 2014; Somyajit et al., 2013; Vassin et al.,
2009), whether and how ATR modulates fork progression upon
stress has been debated. Inactivation of ATR or CHK1 affects
fork progression in unperturbed conditions, mostly as a conse-
quence of deregulated origin firing (Petermann et al., 2006,
2010). Although CHK1 was suggested to actively slow down
replication upon topoisomerase inhibition (Seiler et al., 2007),
assessing reliably whether ATR/CHK1 directly control fork speed
upon genotoxic stress requires genetic uncoupling of their
functions at origins and at active forks. The relevance of ATR
signaling in fork remodeling is also unknown. Yeast studies dis-
played increased reversal of stalled forks upon inactivation of the
replication checkpoint kinase Rad53 (Sogo et al., 2002). A nega-
tive role for ATR in fork reversal was also suggested in human
cells, based on the inhibitory ATR-dependent phosphorylation
of the fork remodeling enzyme SMARCAL1 (Couch et al.,
2013). However, extensive electron microscopy (EM) analysis
upon different treatments revealed no association between
reversed fork frequency and CHK1 phosphorylation (Zellweger
et al., 2015), leaving the question unresolved.
Here, we provide evidence that early RAD51 recruitment dur-
ing ICL replication mediates rapid replication fork reversal upon
ICL induction. Fork remodeling involves far more forks than
those stalled at ICLs andmediates global fork slowing, which as-
sists ICL traverse by single forks and prevents incision-depen-
dent DSBs. ATR signalingmediates both fork reversal and global
fork slowing in response to ICLs and other treatments. Overall,
these data suggest that—besides inhibition of origin firing—
ATR modulates fork speed globally to assist DNA damage
bypass by ongoing forks, thereby promoting genome stability
during replication.
RESULTS
RAD51 Recruitment during ICL Replication Precedes
DSB Formation
To study replication stress associated with ICL-inducing treat-
ments, we treated U2OS cells with trimethylpsoralen (TMP)
combined with UVA treatment, which reportedly induces DNA
lesions with a much higher ICL/monoadducts ratio than cisplatin
or mitomycin C (Huang et al., 2013; Lai et al., 2008). We refined a
previously published protocol for chemical synthesis of digoxy-
genin-tagged TMP (DIG-TMP) (Figure S1A; STAR Methods),
which allows monitoring ICLs by a specific antibody in most
approaches used in this study. We applied TMP and its tagged
derivative to cultured U2OS cells and identified doses of (DIG-)
TMP and UVA inducing—only when combined—delayed pro-
gression through S and G2 phases (Figure S1B). These treat-
ments allow cell cycle resumption and survival of most cells
(Figures S1C–S1E), similarly to mitomycin C (MMC) acute treat-
ments previously used to study ICL repair (Figure S1F)
(Tian et al., 2015). In these conditions, we observed rapid ICL
formation (DIG detection), DNA damage response (DDR)
activation (H2AX phosphorylation, gH2AX), and reduced EdU
incorporation, dependent on the combination of (DIG-)TMP
and UVA treatments (Figures 1A, S2A, and S2B). Furthermore,
these combined treatments induced delayed progression of
ongoing replication forks—detected by DNA fiber analysis—
comparable to mild MMC treatments used in previous studies
(Figure S2C) (Zellweger et al., 2015). As expected, recovery
from ICL-induced DDR activation and cell cycle delay required
FANCD2 (Figures S2D and S2E), a key ICL repair factor (Kotte-
mann and Smogorzewska, 2013). Overall, these sublethal
(DIG-)TMP/UVA treatments recapitulate all expected marks of
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Figure 1. RAD51 Recruitment during ICL Replication Precedes DSB Formation
(A) Immunofluorescence (IF) analysis of gH2AX and DIG in U2OS cells 30 min after optional treatment with DIG-TMP (5 mM) and UVA (3 J/cm2) alone, or in
combination.
(B) Kinetics of DNA double-strand break (DSB) formation assessed by neutral comet assay after ICL induction by TMP (30 nM) and UVA (300 mJ/cm2).
Representative comets (bottom) and statistical analysis (top). At least 50 comets were scored per sample. Kruskal-Wallis test (****p < 0.0001; **p < 0.01; and ns,
not significant).
(C) Kinetics of gH2AX, RAD51, pRPAs4/s8, and DIG at the site of UVA laser irradiation. Representative IF images (left) and percentage of laser-irradiated cells that
were RAD51 or pRPA positive (right).
(D) Colocalization of RAD51 and gH2AX in EdU positive (+) and negative () cells. Cells were treated with DIG-TMP/UVA as in (A) followed by a 15-min EdU pulse.
Experimental setup (left), representative images (middle), and percentage of RAD51-positive cells in EdU+/ cells (right). A minimum of 100 cells was analyzed
per sample.
(C and D) Error bars indicate SD. See also Figures S1 and S2.
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ICL-associated replication stress. Although the DNA lesions
were readily detected within minutes, ICL-associated DSBs are
detected by neutral comet assays only transiently and at later
time points (1–4 hr after treatment; Figure 1B), supporting a
model for ICL repair that invokes slow ICL processing by struc-
ture-specific nucleases and transient DSB formation (Zhang
and Walter, 2014). ICLs and associated marks can also be
induced in subnuclear compartments, by coupling DIG-TMP
treatments with laser-administered UVA light (Figure S3A).
As expected, RPA-s4/s8 phosphorylation—which requires
breakage of the forks challenged by genotoxic stress (Zellweger
et al., 2015)—follows the kinetics of direct DSB detection (Fig-
ures 1B and 1C). However, a significant fraction of DIG-TMP/
UVA-treated cells displayed RAD51 recruitment to ICL-stripes
already 15 min after treatment (Figures 1B and 1C). At this time
point, RAD51 recruitment is largely confined to replicating
(EdU+) cells (Figure 1D). Overall, these data suggest that, using
(DIG-)TMP/UVA, we can monitor induction and repair of
ICLs and associated DSBs. Furthermore, they suggest that
early recruitment of RAD51, preceding ICL-associated DSBs
A
B
Figure 2. Induction of ICLs Reduces Fork
Progression at Damaged, but Also at Undam-
aged Forks
(A) Assessment of DNA synthesis rate (EdU incor-
poration) and DNA damage signaling (gH2AX in-
tensity) in regions of interest (ROIs) (yellow circle)
outside the irradiated area. Experimental setup
(top, left): U2OS cell were treated with DIG-TMP/
UVA and pulsed with EdU—either immediately or
after 45-min recovery. Representative images (top,
right). Statistical analysis of EdU (bottom, left) or
gH2AX (bottom, right) intensity in the ROIs. At least
100 cells were analyzed per sample. Kruskal-Wallis
test (****p < 0.0001). Error bars indicate SD.
(B) Analysis of DNA fiber track length in the pres-
ence or absence of an ICL (indicated by the DIG
label). Experimental setup (top, left). Representative
images for DNA fiber categories (bottom, left). Total
replication tract length (red plus green) was
measured in U2OS cells treated as indicated for
tracts without ICL (no DIG-label, global fork) and
tracts containing an ICL (DIG-label, local fork).
A minimum of 100 tracts was analyzed per sample.
Kruskal-Wallis test (****p < 0.0001; ***p < 0.001).
See also Figure S3.
(Long et al., 2011), reflects a specific func-
tion of the protein during DNA replication.
ICL Induction Reduces Fork
Progression at Damaged and
Undamaged Forks
We next took advantage of local induction
and monitoring of ICLs (Figure S3A) to
assess the global nuclear response to
this treatment, in terms of DNA damage
signaling (gH2AX) and DNA synthesis
rate (EdU incorporation). As expected,
gH2AX and a drastic reduction in EdU sig-
nals were both readily observed at UVA-laser stripes, reflecting
direct replication impairment and DNA damage signaling during
ICL replication (Figure 2A). However, we also observed a signif-
icant reduction of EdU incorporation on subnuclear compart-
ments that were not exposed to UVA irradiation, as early as
15 min after irradiation. A parallel increase in gH2AX was
observed in the same ‘‘undamaged’’ compartments and became
statistically significant 1 hr after the local treatment (Figure 2A). A
reduced rate of DNA synthesis may reflect the reported inhibition
of new origin firing and/or active slowdown of ongoing forks. To
directly assess a possible effect of ICL induction on the global
progression of replication forks, we performed DNA fiber-
spreading assays combined with direct detection of DIG-TMP
lesions, thereby distinguishing ongoing replication forks that
did (local forks) or did not (global forks) encounter an ICL during
the labeling periods (Figures 2B and S3B). In our experimental
conditions, local forks consistently represented z10% of the
total ongoing forks scored in DIG-TMP/UVA-treated cells (Fig-
ure S3C) and expectedly showed amarked decrease in fork pro-
gression rate compared to ongoing forks in untreated cells
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(Figure 2B). Remarkably, the population of global (undamaged)
forks in treated cells also showed slower fork progression
compared to forks from untreated cells. Along with the data in
Figure 2A, these results suggest that a signaling mechanism in-
duces global fork slowing throughout the nuclei of DIG-TMP/
UVA-treated cells.
ICLs Rapidly Induce Frequent Fork Reversal, Dependent
on RAD51 and ZRANB3
We next used psoralen cross-linking coupled to EM (Zellweger
and Lopes, 2018) to investigate in vivo replication fork architec-
A B
C D
E
Figure 3. ICLs Rapidly Induce Frequent
Fork Reversal, Mediated by RAD51 and
ZRANB3
(A) Quantification of single-stranded DNA (ssDNA)
at the replication junction by electron microscopy
(EM). Representative image of a normal replication
fork with magnification of the ssDNA region of in-
terest (top). P, parental strand; D, daughter strand.
Statistical analysis of ssDNA tract length in U2OS
cells, optionally treated with either UVA alone
(3 J/cm2), or DIG-TMP (5 mM) andUVA (3 J/cm2), or
TMP (30 nM) andUVA (300mJ/cm2), and collected
1 hr post-treatment for analysis (bottom). Kruskal-
Wallis test (****p < 0.0001; ns, not significant). Error
bars indicate SD.
(B) Quantification of reversed replication forks by
EM in U2OS cells treated as in (A). Representative
image of a reversed fork (top) and statistical
analysis (bottom). P, parental strand; D, daughter
strand; R, regressed arm.
(C) Quantification of reversed forks in U2OS cells
treated with TMP/UVA as in (A) but collected
already 15 min post-irradiation.
(D) Percent reversed forks detected by EM in
U2OS cells transfected with siLuc (control) or
siRAD51 and treated optionally with TMP /UVA as
in (A) (left). Western blot showing the down-
regulation of RAD51 protein levels (right). TFIIH,
loading control.
(E) Percentage of reversed forks in ZRANB3-pro-
ficient (ZRANB3 wild-type [WT]) and ZRANB3-
deficient (ZRANB3 KO) U2OS cells, which were
optionally treated with TMP /UVA as in (A) (left).
Western blot showing the absence of the ZRANB3
protein in ZRANB3-KOU2OS cells (right). GAPDH,
loading control.
(A–E) A minimum of 70 forks were analyzed in two
independent experiments. See also Table S1.
ture. This approach allows monitoring
ssDNA accumulation and/or the conver-
sion of replication forks into four-way
junctions, known as reversed forks (Ray
Chaudhuri et al., 2012; Zellweger et al.,
2015). Both TMP and DIG-TMP treat-
ments—coupled to UVA irradiation—
lead to significant accumulation of ssDNA
at replication forks (Figure 3A), which is a
knownmarker of replication stress (Saldi-
var et al., 2017). Also, both treatments
lead to the reversal of 20%–25% of the forks (Figure 3B;
Table S1A). This cellular response is remarkably fast, as an in-
crease in reversed fork frequency over background levels was
observed as early as 15 min after treatment (Figure 3C; Table
S1B). The central recombinase RAD51 and the DNA translocase
ZRANB3 have been recently shown to mediate fork reversal
using different genotoxic treatments and multiple genetic tools
(Vujanovic et al., 2017; Zellweger et al., 2015). Using the same
experimental setup, we confirmed that both factors are also
strictly required for reversed fork formation upon treatment
with ICL-inducing agents (Figures 3D and 3E; Tables S1C and
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Figure 4. Impairing Fork Reversal Globally Affects Fork Slowing and Leads to ICL Incision-Dependent Breaks
(A and B) DNA fiber analysis (as in Figure 2B) in U2OS cells transfected with siLuc (control) or siRAD51 (A) or that were proficient (ZRANB3 WT) or deficient for
ZRANB3 (ZRANB3 KO) (B). A minimum of 100 tracts was measured per sample. Kruskal-Wallis test (****p < 0.0001; **p < 0.01, 05; ns, not significant).
(C and D) Quantification of the olive tail moment by neutral comet assay in U2OS cells transfected with siLuc or siRAD51 (C) or in either ZRANB3 WT or ZRANB3
KO U2OS cells (D)—both optionally treated with TMP (30 nM) and UVA (300 mJ/cm2).
(legend continued on next page)
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S1D). These results also suggest that the fast recruitment of
RAD51 to ICLs observed in replicating cells (Figures 1C and
1D) likely mediates prompt fork remodeling, as opposed to HR
repair of ICL-associated DSBs.
Fork Reversal Mediates Global Fork Slowing and Limits
ICL Incision-Dependent DSBs
Restraining replication fork progression was recently reported as
a key function of FA factors in response to ICL (Lachaud et al.,
2016). Active fork slowing upon genotoxic stress has been pre-
viously linked to replication fork reversal (Vujanovic et al., 2017;
Zellweger et al., 2015). As we now report that fork slowing is
not limited to damaged forks, but extends to undamaged forks
throughout the nucleus (Figure 2), we assessed a potential role
of fork reversal in ICL-induced global fork slowing. Using the
experimental conditions described above, we performed DNA
fiber assays in U2OS cells upon inactivation of RAD51 or
ZRANB3, and found that both conditions impairing fork reversal
also significantly affected global fork slowing upon DIG-TMP/
UVA treatment (Figures 4A and 4B). Moreover, PARP inhibi-
tion—which was also reported to affect reversed fork accumula-
tion (Berti et al., 2013; Ray Chaudhuri et al., 2012; Zellweger
et al., 2015)—led to unrestrained fork progression upon ICL in-
duction (Figure S4A). Neutral comet assays revealed that all of
these genetic conditions of impaired fork slowing and reversal
were consistently associated with a significant increase of chro-
mosomal breakage early after TMP/UVA treatment (1 hr; Figures
4C–4E). Similar results were obtained when RAD51 inactivation
was performed by a different small interfering RNA (siRNA) or
in the untransformed RPE-1 cell line (Figures S4B and S4C).
We next used stable U2OS-derived cell lines to downregulate
and conditionally re-express wild-type or mutant SLX4 (Guervilly
et al., 2015)—a key nuclease scaffold regulating ICL incision ac-
tivities (Klein Douwel et al., 2014)—and found that the increased
chromosomal breakage observed upon impaired fork slowing
and reversal depends on SLX4 and on its functional interaction
with the XPF nuclease (Figures 4E, 4F, S4D, and S4E), both of
which are strictly required for ICL unhooking (Klein Douwel
et al., 2014). Accordingly, the accumulation of ICL-associated
breaks in ZRANB3-defective cells depends on the ICL-process-
ing factor FANCD2, but not on MUS81 (Figures 4G and S4F),
which is dispensable for ICL unhooking (Klein Douwel et al.,
2014). These results suggest that fork reversal mediates global
fork slowing and prevents SLX4/XPF-dependent DSB formation
at local forks by deregulated ICL unhooking. In keeping with
these results, we found that ZRANB3 is required to limit chromo-
somal abnormalities upon ICL-inducing treatments (MMC; Fig-
ure 4H)—as previously shown for other DNA-damaging agents
(Ciccia et al., 2012; Yuan et al., 2012)—and significantly contrib-
utes to cell survival upon MMC or TMP/UVA treatments (Figures
4I and 4J). Overall, these data support the relevance of replica-
tion fork remodeling for genome integrity and cell survival upon
ICL induction.
Fork Reversal Promotes ICL Traverse, Independently of
FANCM
We further assessed how replication fork remodeling contributes
to ICL replication, focusing on the forks directly challenged by
the lesions. We used the DNA fiber assays coupled to DIG-
TMP treatment and detection (Huang et al., 2013), and confirmed
in U2OS cells that around 60% of the forks are able to traverse
through ICLs as single forks, while a minority of forks is either
transiently stalled at the lesion (z25%) or converging at the
lesion with a second fork (z15%) (Figure 5A) (Huang et al.,
2013). ICL traverse is also very efficient in mouse embryonic
fibroblasts and does not require a specific glycosylase (i.e.,
Neil3; Figure S4G), whichwas recently shown to provide an alter-
native ICL-unhooking mechanism in Xenopus egg extracts
(Semlow et al., 2016). Inactivation of either RAD51 or ZRANB3
led to a significant increase in replication fork stalling and a par-
allel decrease in ICL traverse, while the frequency of converging
forks was unchanged (Figures 5B and 5C). Thus, global fork
slowing and reversal is required for efficient ICL traverse.
As ICL traverse was shown to depend on the DNA translocase
FANCM (Huang et al., 2013)—which is capable of reversing syn-
thetic forks in biochemical experiments (Gari et al., 2008)—we
directly assessed its contribution by effective siRNA-mediated
downregulation. As reported (Huang et al., 2013), FANCMdeple-
tion affected ICL traverse, to a similar extent as RAD51 or
ZRANB3 inactivation (Figures 5B–5D). However, neither ICL-
induced fork reversal nor global fork slowing were affected by
FANCM depletion (Figures 5E, S4H, and S4I; Table S2). These
data suggest that global fork slowing and reversal occur up-
stream of ICL traverse and that FANCM promotes ICL traverse
via alternative transactions occurring locally at ICL-damaged
forks.
ICL Traverse Can Be Visualized as Postreplicative Sister
Chromatid Junctions, Resolved by ICL Incision
An important implication of ICL traverse by single forks is that
ICL unhooking should frequently occur post-replicatively—i.e.,
after ICL traverse—allowing to physically separate replicated
(E) FIT-inducible SLX4WT and SLX4 FLW cells, transfected with siRNA against 30 UTR of endogenous SLX4, and, where indicated, treated with Dox (1 ng/mL) in
order to express exogenous SLX4 wild-type (SLX4 WT) or mutant (SLX4 FLW) protein. All cells were optionally treated with TMP/UVA (as in C), PARP inhibitor
(Olaparib [OLA]; 10 mM), and processed for neutral comet assays.
(F) FIT-inducible SLX4 wild-type cells were transfected with siRNA against 30 UTR of SLX4 and siLuc or siRAD51 and, 20 hr later, incubated with Dox for 16 hr.
Cells were optionally treated as in (C) and processed for neutral comet assays.
(G) ZRANB3 WT or ZRANB3 KO U2OS cells were transfected with siLuc, siMUS81, or siFANCD2. 48 hr later, the cells were optionally treated as in (C) and
processed for neutral comet assay. In (C)–(G), at least 50 comets were scored per sample. Kruskal-Wallis test (****p < 0.0001; ***p < 0.001; ns, not significant).
(H) Number of chromosomal abnormalities per indicated cell line, as determined by metaphase spreading upon optional 20-hr MMC treatment (75 nM), followed
by 16-hr nocodazole treatment (200 ng/mL).
(I and J) ZRANB3 WT or ZRANB3 KO U2OS cells were left untreated or treated with TMP (30 nM) plus UVA (300 mJ/cm2) (I) or treated for 8 hr with the indicated
doses of MMC (J) to assess colony formation.
(H–J) Error bars indicate SD. See also Figure S4.
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duplexes behind the forks. Evidence for this has been so far
limited to multicolor DNA fiber experiments performed in Chi-
nese hamster cells (Huang et al., 2013). We thus set out to pro-
vide direct visualization of ICL traverse in human cells and to
study the role of ICL unhooking in fork transactions at ICLs.
Using DNA fiber and EM analysis, we found that abolishing ICL
unhooking by SLX4 downregulation had no visible effect on the
efficiency of ICL traverse or on the frequency of TMP/UVA-
induced reversed forks, suggesting that ICL unhooking does
not contribute to global fork remodeling or ICL replication bypass
(Figures 6A and 6B; Table S3). We then carefully inspected the
architecture of replication forks upon TMP/UVA treatment,
performing our EM analysis with low DNA concentration, to
minimize accidental inter- or intra-molecular crossings of DNA
strands. ICL traverse events are expected to move ICLs behind
replication forks, resulting in detectable sister chromatid junc-
tions at symmetric distance from the fork (postreplicative junc-
tions [PRJs]; Figure 6C) or in symmetric X-shaped molecules
(Figure 6D), when fork and junction are separated by restriction
digestion. In these experimental conditions, crossings of repli-
A
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ED
Figure 5. Fork Reversal Promotes ICL Tra-
verse in a FANCM-Independent Manner
(A) DNA fiber tracks were generated as in Fig-
ure 2B. Schematic display of local replication
patterns containing an ICL (DIG-label, pink)—such
as stalled forks, converging forks, and fork traverse
(left). Representative images of local replication
patterns (middle). Frequency of the replication
patterns observed in local forks (right). A minimum
of 100 tracts was analyzed per experiment.
(B) Frequency of local replication patterns (as in A)
in U2OS cells transfected with siLuc or si RAD51.
(C) Frequency of local replication patterns (as in A)
in ZRANB3 WT or ZRANB3 KO cells.
(D) Frequency of local replication patterns (as in A)
in U2OS cells transfected with siLuc (control) or
with an siFANCM. In (B)–(D), a minimum of 100
forks was analyzed.
(E) Percentage of reversed forks detected by EM in
U2OS cells transfected with siLuc (control) or si-
FANCM—treated 48-hr post transfection with TMP
(30nM)andUVA (300mJ/cm2).Cellswerecollected
1 hr after irradiation. A minimum of 70 forks were
analyzed in two independent experiments.
(A–D)Errorbars indicateSD.SeealsoFigureS4and
Table S2.
cated duplexes behind forks (postrepli-
cative junctions) or X-shaped molecules
were extremely rare in untreated cells
(<1%; Figure 6E; Table S4). Furthermore,
the rare four-way junctions identified in
untreated cells displayed contour-length
measurements expected for reversed
forks (Figures 6B)—i.e., only two of the
four arms equal in length, as typically
observed in 3%–5% of the forks in un-
treated U2OS cells (Zellweger and Lopes,
2018; Zellweger et al., 2015). Although
reversed forks expectedly increased upon TMP/UVA treatment,
both postreplicative junction and symmetric X-molecules were
only rarely observed in control U2OS cells (2%–3%; Figures
6B and 6E; Tables S3 and S4). However, when ICL unhooking
was prevented by SLX4 depletion, z7% of replication forks
(20 out of 295 intermediates) in TMP/UVA-treated cells displayed
a junction between replicated duplexes, positioned at symmetric
distance from the fork (postreplicative junctions; Figures 6C, 6E,
and S5A–S5D; Table S4). Analogously, besides ICL-induced
reversed forks (Figure 6B), several additional four-way junctions
(z3%, 9 out of 295 intermediates) were observed in TMP/UVA-
treated SLX4-depleted cells and displayed symmetric length of
the four arms (Xs; Figures 6D, 6E, and S5E–S5H; Table S4).
These observations strongly suggest that forks efficiently tra-
verse ICLs in human cells, generating sister chromatid junctions
(postreplicative junctions + Xs) that are rapidly resolved by SLX4-
dependent ICL unhooking. Accordingly, these molecules accu-
mulated in TMP/UVA-treated cells also upon XPF inactivation,
but not upon MUS81 defects (Figures 6F and S6A; Table S5),
reflecting the different contribution of these nucleases to ICL
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unhooking (Klein Douwel et al., 2014). Furthermore, postreplica-
tive junction+X accumulation in TMP/UVA-treated SLX4-defec-
tive cells was largely dependent on FANCM (Figure 6G; Table
S6), which was previously shown to mediate efficient ICL tra-
verse (Huang et al., 2013). Finally, we optimized experimental
conditions for the specific binding of a gold-conjugated anti-DIG
antibody to genomic DNA extracted fromDIG-TMP/UVA-treated
cells, in order to directly reveal ICLs at individual intermediates
(Figures S6B–S6D). Only a fraction of ICL-containing molecules
is efficiently bound by the antibody, and we cannot exclude
a bias toward/against binding of specific intermediates, which
prevents using this method for quantitative analyses. However,
we did observe antibody binding at a subset of replication
intermediates consistent with fork stalling/convergence at ICLs
(Figures S6E and S6F). Importantly—although the complex
architecture of ICL traverse intermediates favored in vitro intra-
molecular interactions and antibody clumping (Figure S6G), pre-
venting reliable identification of several traverse intermediate
candidates—it was occasionally possible to observe antibody
binding also at postreplicative junctions behind a replication
fork (Figure 6H). Altogether, the available set of EM data sug-
gests that ICL traverse is frequent and can be directly visualized
in human cells.
ATR Modulates Global Fork Slowing and Reversal upon
ICL Induction and Other Genotoxic Treatments
The reduction in DNA synthesis reported above upon ICL induc-
tion is accompanied by replication fork slowing and reversal, and
by a parallel increase in gH2AX in replicating cells, suggesting a
role for ATR-dependent signaling in these mechanisms. ATR in-
hibition by AZ20 (Foote et al., 2013) expectedly increased EdU
incorporation, likely reflecting unleashed origin firing (Karnani
and Dutta, 2011). Indeed, by preventing de novo origin firing,
CDC7 inhibition by XL413 suppresses this effect and allows
focusing on the effects of ATR inhibition on ongoing forks (Fig-
ures 7A, S7A, and S7B). In these experimental conditions,
TMP/UVA treatment reduced DNA synthesis by limiting the pro-
gression of active forks. Remarkably, this effect was completely
abolished by ATR inhibition (Figure 7B), which also suppressed
TMP/UVA-induced gH2AX, despite comparable levels of
induced ICLs (Figures 7C and S7C–S7E). Very similar observa-
tions were made measuring EdU incorporation at a distance
A B E
C D F
H
G
Figure 6. Visualization of ICL Traverse as
Postreplicative Sister Chromatid Junctions,
Resolved by ICL Incision
(A) Frequency of local replication patterns (as in
Figure 5A) in FIT-inducible SLX4 proficient
(SLX4+) or deficient (SLX4) cells (as in Figure 4E).
A minimum of 100 forks was analyzed per exper-
iment.
(B and E) Frequency of local replication patterns
determined by EM, such as reversed forks (B),
postreplicative junctions (PRJs) and X-shaped
molecules (E) in SLX4+ and SLX4 cells that were
either left untreated or treated with TMP/UVA
(30 nM/300 mJ/cm2). A minimum of 70 forks
was analyzed per sample in two independent
experiments.
(C and D) Representative electron micrograph
showing a postreplicative junction behind a repli-
cation fork, indicative of ICL traverse (C) or an
X-shaped molecule (D).
(F) Total frequency of postreplicative junction +
X-shapedmolecules fromU2OS cells, transfected
with siLuc, siXPF, or siMUS81 and treated with
TMP/UVA (30 nM/300 mJ/cm2). A minimum of
70 forks was analyzed per sample in two inde-
pendent experiments.
(G) Total frequency of postreplicative junction +
X-shaped molecules in SLX4 cells (as in Fig-
ure 4E) transfected with siLuc or siFANCM and
treated with TMP (30 nM) and UVA irradiated
(300 mJ/cm2). A minimum of 70 forks was
analyzed per sample.
(H) Representative image showing a post-
replicative junction behind a replication fork,
indicative of ICL traverse. ICL labeled with an
antibody against DIG. See also Figures S5 and S6
and Tables S3–S6.
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from laser-induced ICL stripes, using the approach described in
Figure 2A. Also, in this case, ATR inhibition impaired H2AX phos-
phorylation and triggered unrestrained DNA synthesis in laser-
irradiated nuclei, despite simultaneous inhibition of CDC7, and
thus independently of de novo origin firing (Figures 7D and 7E).
Analogous results on DNA synthesis and gH2AX were obtained
combining CDC7 inhibition with a second ATR inhibitor (VE821;
Figures S7F and S7G). As for all other conditions impairing global
fork slowing (Figures 4 and 5), ATR inhibition also impaired effi-
cient ICL traverse at local forks (Figure 7F).
As we observed a tight association between global fork slow-
ing, ICL traverse, and fork reversal (Figure 4), we directly as-
sessed by EM the effect of ATR inhibition on fork reversal upon
ICL induction. ATR inhibition completely suppressed TMP/
UVA-induced fork reversal, even when unscheduled origin firing
was prevented by CDC7 inhibition (Figure 7G; Table S7A). We
next tested whether ATR role in fork reversal extended to other
conditions of replication interference, previously reported to
induce frequent fork remodeling (i.e., topoisomerase I inhibition
by camptothecin [CPT]; nucleotide depletion by hydroxyurea
[HU]) (Zellweger et al., 2015). Upon all tested treatments, ATR
inhibition completely abolished drug-induced fork reversal (Fig-
ure 7H; Table S7B). Collectively, these results suggest that
ATR activation upon various types of replication stress gener-
ates an active signal to promote global fork slowing and reversal,
which extends to forks that are not directly challenged by DNA
lesions.
DISCUSSION
Replication fork reversal was previously reported as a general
response to multiple genotoxic treatments, including ICL-
inducing agents like cisplatin and MMC (Zellweger et al., 2015).
Albeit not surprising, the observation that fork reversal occurs
frequently upon (DIG-)TMP/UVA treatments is important to un-
derstand ICL replication and processing in human cells, as these
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Figure 7. ATR Modulates Global Fork Slow-
ing and Reversal upon ICL Induction and
Other Genotoxic Treatments
(A and B) EdU incorporation by FACS analysis:
U2OS cells were incubated for 30 min without (A) or
with (B) TMP (30 nM), AZ20 (ATR inhibitor, 1 mM),
CDC7i (XL413, 10 mM), or in all possible combina-
tions of the three, followed by irradiation with UVA
(300 mJ/cm2). EdU (10 mM) incorporation was al-
lowed for 30min in the presence or absence of AZ20
(ATR inhibitor, 1 mM), CDC7i (XL413, 10 mM), or both.
EdU intensity values in S-phase cells were extracted
for a minimum of 400 random cells per sample.
Kruskal-Wallis test (****p < 0.0001; ns, not signifi-
cant).
(C) Cells were treated as in (A) and (B) and stained
with an antibody against gH2AX. gH2AX intensity
values from 400 random S-phase cells were ex-
tracted. Kruskal-Wallis test (****p < 0.0001).
(D and E) U2OS cells were incubated with or without
DIG-TMP (5 mM), AZ20 (ATR inhibitor, 1 mM), and
CDC7i (XL413, 10 mM) for 30 min in the indicated
combinations. Cells were irradiated using a UVA
laser. EdU Click-iT and IF was performed for EdU
and gH2AX, respectively. EdU (D) and gH2AX (E)
intensities in ROIs (as described in Figure 2A) were
determined using ImageJ.
(F) DNA fiber analysis of local replication patterns
(displayed in Figure 5A) was combined with the
presence or absence of ATR inhibitor (AZ20, 1 mM).
Error bars indicate SD.
(G) Percentage of reversed forks assessed by EM in
untreated U2OS cells or cells treated with TMP
(30 nM), AZ20 (ATR inhibitor, 1 mM), CDC7i (XL413,
10 mM), or in all possible combination of the three. A
minimum of 70 forks was analyzed in two indepen-
dent experiments.
(H) Percentage of reversed forks assessed by EM in
U2OS cells left untreated or pre-incubated for
30 min with ATR inhibitor (AZ20, 1 mM). Following
pre-incubation, cells were treated, where indicated,
with camptothecin (CPT) (25 nM) or hydroxyurea
(HU) (500 mM) for 1 hr. A minimum of 70 forks was
analyzed in two independent experiments. See also
Figure S7 and Table S7.
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compounds induce a much higher ICL/monoadduct (MA) ratio
than cisplatin or MMC (Huang et al., 2013; Lai et al., 2008).
Furthermore, DIG-TMP treatment provides a unique opportunity
to distinguish forks directly challenged by ICLs (local forks) from
those that do not encounter ICLs (global forks), enabling assess-
ment of the relevance of fork slowing and reversal in both con-
texts. In our experimental conditions, only z10% of the forks
replicate across an ICL within 1 hr after treatment (Figures S3C
and S3D). Of these, only z25% (i.e., 2.5% of total forks) are
stalled at ICLs at any given time (Figure 5A). Based on the
frequency of reversed forks observed in the same experimental
conditions (20%–25% of total forks), we conclude that the vast
majority of reversal events occur at a distance from ICL. We
propose that fork reversal mostly occurs as a result of a signaling
mechanism—emanating from the damage itself, its processing,
and/or the first few forks dealing with it—ultimately involving a
high fraction of the forks. In light of the tight association between
fork reversal and fork slowing observed here and in previous
studies (Kile et al., 2015; Ray Chaudhuri et al., 2012; Vujanovic
et al., 2017; Zellweger et al., 2015), we envision global fork
reversal as a molecular switch to provide more time for the
template to be repaired before duplication by ongoing forks.
This cellular response may be particularly relevant in face of
ICLs, as their removal requires DNA incision events that are
potentially risky in close vicinity to replication forks. ICL recogni-
tion and repair were previously shown to occur on non-repli-
cating dsDNA (Williams et al., 2013). In fact, biochemical
evidence suggests that ICL unhooking by SLX4/XPF may be
inhibited next to stalled forks and require RPA recruitment to
exposed ssDNA (Abdullah et al., 2017). We thus propose that
global fork reversal promotes ICL repair on the double-stranded
template by transiently delaying global fork progression, thereby
avoiding untimely and excessive ICL encounters by forks and
limiting SLX4-dependent fork breakage (Figure S7H, I–III).
As replication-independent ICL repair was shown to activate
ATR in Xenopus egg extracts (Williams et al., 2013), it will be
important to assess whether in human cells this pathway is
also active in S phase and liaises with ATR-mediated control of
fork progression.
While assisting template repair and limiting dangerous fork
processing events, active slowing and reversal appears to
mediate also efficient ICL traverse by those forks that meet
unrepaired ICLs (Figure S7H, IV). By EM analysis in SLX4-
defective cells, we provide here direct visualization of these
ICL traverse intermediates as postreplicative junctions of
daughter duplexes behind moving forks (postreplicative junc-
tion+Xs; Figure 6). The low number of these junctions observed
in SLX4-proficient cells—and their preferential visualization in
close proximity to forks (i.e., postreplicative junction > Xs)—
suggest that the kinetics of postreplicative ICL unhooking is
very fast and mechanistically coupled with ICL traverse. We
propose that efficient ICL traverse promotes ICL unhooking
on postreplicative dsDNA and helps uncoupling ICL processing
from the forks, thereby limiting potentially cytotoxic fork
breakage (Figure S7H, V and VI). Furthermore, performing ICL
repair at postreplicative junctions may be coupled to strand
annealing events, in order to limit DSB formation upon ICL
incision (Figure S7H, VII and VIII), as already proposed at
converging forks (Zhang and Walter, 2014). While these fork re-
modeling-associated ICL tolerance mechanisms provide only a
limited contribution to the resistance of wild-type cells to ICL-
inducing treatments (Figure 4J), they may represent crucial
modulators of chemosensitivity upon hypomorphic DSB repair
defects, which are frequently found in tumors and limit ICL
repair capacity.
It is currently unclear whether, besides global regulation of fork
progression, fork remodeling in proximity to the lesions may also
participate directly in the mechanism of ICL traverse or in pro-
moting fork fusion at ICLs. In the context of fork fusion—which
is rapidly observed at all ICL-containing plasmids replicating in
Xenopus egg extracts (Ra¨schle et al., 2008)—fork reversal was
recently shown to follow replisome disassembly and, similarly
to what proposed above for single ongoing forks, may promote
ICL processing on the reannealed parental duplex (Amunugama
et al., 2018). On human chromosomes, where most ICLs are
bypassed by single forks (Figure 5) (Huang et al., 2013), fork
reversal may in principle promote the required reorganization
and/or translocation of replisome components across the ICL
to assist fork restart beyond the ICL. By extending the linear
DNA duplex between the fork junction and the ICL, fork reversal
might prime replicative helicase remodeling from an ssDNA to a
dsDNA configuration, thus allowing its sliding past the lesion, as
previously suggested (Huang et al., 2013). Similarly, although we
propose that ATR assists ICL traverse by promoting fork
reversal, our data do not exclude direct ATR-dependent modifi-
cations of the replisome and accessory proteins, to mediate
template unwinding and fork restart beyond ICLs. Assessing
directly the role of ATR and the relevance of fork reversal in
ICL traverse will require careful biochemical reconstitution of
the traverse reaction.
FANCMwas previously shown to remodel forks in biochemical
assays (Gari et al., 2008) and was reported to promote efficient
ICL traverse (Huang et al., 2013). While our data confirm the
role of FANCM in ICL traverse, it also excludes a detectable
contribution to global fork slowing and reversal in human cells.
These data further suggest that replication fork reversal occurs
upstream of ICL traverse and that FANCM may be involved in
a specialized fork restart pathway enabling ICL traverse from
previously reversed forks. This hypothesis is consistent with
the reported defect of FANCM-defective cells in restarting
stalled forks (Schwab et al., 2010) and will require further
investigation.
Previous parallel analyses of fork architecture and checkpoint
activation in response to several genotoxic treatments had failed
to find linear correlations between replication fork reversal and
detectable activation of the ATR or ATM pathways (Zellweger
et al., 2015). It should be noted, however, that activation of
ATR/ATM was assessed monitoring phosphorylation events on
specific targets (CHK1 and KAP1, respectively), which may not
be necessarily relevant for ATR-mediated regulation of fork pro-
gression. In keeping with this, FANCM-defective cells are report-
edly inefficient in global ATR signaling—e.g., CHK1-, p53-, or
SMC1 phosphorylation (Collis et al., 2008; Huang et al., 2010;
Schwab et al., 2010)—but displayed no defect in global fork
slowing and reversal in our study. A direct link between ATR acti-
vation and slower progression of ongoing forks has been difficult
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to assess, mainly because of the reported effects on origin firing
and its indirect impact on fork progression (Petermann et al.,
2006, 2010). Uncoupling the two effects by simultaneous
CDC7 inhibition, and monitoring directly damaged and undam-
aged forks by DIG-TMP detection, we now report that ATR
activity promotes fork slowing and reversal of a large fraction
of replication forks, including those that are not directly chal-
lenged by ICLs. As we observed similar effects on fork reversal
upon different types of replication stress, it is most likely that
this ATR-mediated cross talk between damaged and undam-
aged forks is part of a general response to genotoxic stress,
possibly related to the recently reported metabolic control of
fork progression rates (Somyajit et al., 2017). Our observations
open the exciting perspective of exploring alternative ATR
targets regulating progression and stability of ongoing forks. In
light of the high number of reported ATR targets among repli-
some components, accessory factors, and HR proteins (Ahlskog
et al., 2016; Errico and Costanzo, 2012; Lossaint et al., 2013;
Murphy et al., 2014; Somyajit et al., 2013; Vassin et al., 2009),
this open question should be tackled thoroughly in a new
exciting avenue of research.
Intriguingly, fork reversal was reported to be increased
at stalled forks upon inactivation of the yeast replication check-
point kinase Rad53 (Sogo et al., 2002). It should be noted,
however, that fork reversal in yeast is abundant only upon
topoisomerase I inhibition (Ray Chaudhuri et al., 2012), and
that an increase in checkpoint-defective cells is only clearly
detected upon nucleotide depletion (Lopes et al., 2006; Sogo
et al., 2002). Similarly, ATR inhibition in human cells was shown
to induce SMARCAL1-dependent exposure of native ssDNA,
which was interpreted as accumulation of reversed forks with
paired nascent strands of unequal length (Couch et al., 2013).
However, this was observed only upon prolonged nucleotide
depletion and simultaneous deregulation of origin firing by
ATR inhibition. In both contexts, reversed forks and/or other
intermediates exposing nascent ssDNA may accumulate as a
pathological consequence of massive ssDNA accumulation—
which was found to directly correlate with reversed fork fre-
quency (Zellweger et al., 2015)—rather than reflecting an active
role of the replication checkpoint in preventing fork remodeling
upon genotoxic stress.
How is ATR initially activated, to spread a signal for global
fork reversal? An accumulation of ssDNA at replication forks is
detectable upon all tested genotoxic treatments (Figure 3) (Zell-
weger et al., 2015). This may reflect uncoupled DNA synthesis
and/or regulated fork resection in proximity to DNA lesion, and
may well account for initial ATR activation. However, it is also
possible that intermediates of ICL processing ahead or behind
replication forks contribute to boost ATR activation and phos-
phorylation of the relevant targets. Interestingly, fork reversal
observed in unperturbed cells—likely occurring at endogenous
difficult-to-replicate regions—is uncoupled from globally
detectable ATR signaling and H2AX phosphorylation (Figure 7H)
(Schmid et al., 2018).
Our data may be relevant in light of the promise of ATR inhib-
itors in cancer chemotherapy. We note that unrestrained fork
progression and defective fork reversal upon replication stress
are induced by both PARP (Ray Chaudhuri et al., 2012) and
ATR inhibitors (this study), both of which hold great promise as
therapeutic agents, particularly in combination with other geno-
toxic treatments. It is thus tempting to speculate that both
treatments affect crucial fork protection mechanisms, thereby
promoting DSB accumulation upon endogenous or exogenous
replication stress. The identification of key ATR targets or sepa-
ration-of-function mutations will allow testing the specific contri-
bution of this function of the ATR checkpoint in the promising
cytotoxicity observed in cancer cells upon ATR inhibition.
Finally, our data suggest that combining DIG-TMP/UVA-
based DNA fiber-spreading and comet assays may be highly
predictive of cancer-specific responses to chemotherapeutic
regimens with ICL-inducing agents. Testing this possibility in
relevant patient-derived samples may pave the way to use func-
tional replication tests as standard predictive assays for person-
alized medicine in clinical oncology.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-DIG antibody Abcam Cat# ab76907, RRID:AB_1523496
anti-DIG antibody Abcam Cat# ab420, RRID:AB_304362
anti-XPF Bethyl laboratories Cat# A301-315A, RRID:AB_938089
anti-MUS81 Sigma-Aldrich Cat# M1445, RRID:AB_532259
anti-gH2AX antibody EMD Millipore Cat# 05-636, RRID: AB_309864
anti-RPA pS4/S8 Bethyl laboratories Cat# A300-245A, RRID:AB_309864
anti-RAD51 Bio Academia Cat# 70-002
anti-mouse Alexa 594 Life technologies Cat# A11032, RRID:AB_141672
anti-rabbit Alexa 488 Life technologies Cat# A11008, RRID:AB_143165
anti-rabbit Alexa 594 Life technologies Cat# A11037, RRID:AB_2534095
anti-mouse Alexa 647 Life technologies Cat# A21235, RRID:AB_141693
anti-mouse Alexa 488 Life technologies Cat# A10011, RRID: AB_2534069
anti-goat Alexa 647 Life technologies Cat# A21447, RRID:AB_141844
anti-rat Cy3 Jackson ImmunoResearch Cat# 712-165-513, RRID: AB_2340669
anti-CHK1pS345 Cell Signaling Techn Cat# 2348, RRID: AB_331212
anti-CHK1 Santa Cruz Cat# sc-8408, RRID: AB_627257
anti-Rad51 Santa Cruz Cat# sc-8349, RRID: AB_2253533
anti-ZRANB3 Bethyl laboratories Cat# A303-033A, RRID:AB_10773114
anti-FANCM Prof A. Constantinou lab N/A
anti-GAPDH Millipore Cat# MAB374, RRID: AB_2107445
anti-mouse HRP conjugate GE Healthcare Cat# NA931V
anti-rabbit HRP conjugate GE Healthcare Cat# NA934V
Rat anti-BrdU/CldU Abcam Cat# ab6326, RRID:AB_305426
Mouse anti-BrdU/IdU BD Biosciences Cat# 347580, RRID: AB_10015219
Chemicals, Peptides, and Recombinant Proteins
DIG-TMP Synthesized for this study N/A
TMP Sigma-Aldrich Cat# T6137
2-Mercaptoethanol Sigma-Aldrich Cat# M3148
Lipofectamine RNAiMAX Transfection Reagent Thermo Fisher Scientific Cat# 13778-500
cis-Diammineplatinum(II) dichloride Sigma-Aldrich Cat# P4934
Protease Inhibitor Cocktail Sigma-Aldrich Cat# P8340
ECL Advance Blocking Reagent GE HealthCare Cat# RPN418V
Doxycycline hyclate Sigma-Aldrich Cat# D9891
5-Chloro-20-deoxyuridine Sigma-Aldrich Cat# C6891
5-Iodo-20-deoxyuridine Sigma-Aldrich Cat# I7125
Proteinase K, recombinant, PCR Grade Sigma-Adrich Cat# 03115852001
Blasticidin InvivoGen Cat# ant-bl-1
Hygromycin InvivoGen Cat# ant-hg-1
Doxycyclin Sigma-Aldrich Cat# D9891
Olaparib Selleckchem Cat# S1060
AZ20 (ATRi) Selleckchem Cat# S7050
VE821 (ATRi) Selleckchem Cat# 8007
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to, and will be fulfilled by, the lead contact, Prof.
Massimo Lopes (lopes@imcr.uzh.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Origins of cell lines used in this study are reported in the key resources table.
METHOD DETAILS
Cell Culture and Cell Lines
U20S cells, ZRANB3 proficient and deficient U2OS cells (kind gift from Dr. David Cortez) and SLX4 Flp-In-TRex U2OS cells (kind gift
from Dr. Pierre-Henri Gaillard), as well as Neil3 proficient and deficient MEFs (kind gift fromDr. Lusia Luna) were used in this study. All
cell lines were cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% FBS, 100U/mL Penicillin and
10 mg/mL Streptomycin (complete media). Cells were incubated at 37C in 5% CO2. For SLX4 cells, 2mg/ml Blasticidin and
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
XL413 (CDC7i) Selleckchem Cat# S7547
PvuII high fidelity New England Biolabs Cat# R3151S
Critical Commercial Assays
Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit (FACS) Thermo Fisher Scientific Cat# C10425
Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit
(Immunofluorescence)
Thermo Fisher Scientific Cat# C10337
Comet Assay 2 Well ES Unit with Starter Kit Trevigen Cat# 4250-050-ESK
Deposited Data
Raw imaging data This paper https://data.mendeley.com/datasets/
c2cdh5vfwh/draft?a=56718611-3cfd-
4946-9eae-b8f0b4e31994
Experimental Models: Cell Lines
U2OS ATCC HTB-96
ZRANB3 WT U2OS David Cortez lab N/A
ZRANB3 KO U2OS David Cortez lab N/A
SLX4 Flp-In-TRex U2OS Pierre-Henri Gaillard lab N/A
Neil3 WT MEFs Lusia Luna lab N/A
Neil3 KO MEFs Lusia Luna lab N/A
Oligonucleotides
siRAD51 F_1: GACUGCCAGGAUAAAGCUUdTdT Microsynth N/A
siRAD51 F_2: GUCCUGCAGCCUAAUGAGAdTdT Microsynth N/A
siSLX4: GCACAAGGGCCCAGAACAAdTdT Microsynth N/A
siFANCM: AAGCUCAUAAAGCUCUCGGAAdTdT Microsynth N/A
siFANCD2: CAGAGUUUGCUUCACUCUCUAdTdT Microsynth N/A
siMUS81: CAGCCCUGGUGGAUGGAUAdTdT Microsynth N/A
siXPF: GUAGGAUACUUGUGGUUGAdT dT Microsynth N/A
Software and Algorithms
GraphPad Prism6 and 7 for MAC OS X GraphPad Software https://www.graphpad.com/
ImageJ (DNA fiber length analysis, Immunofluorescence, Comet
and EM data)
ImageJ Software https://imagej.nih.gov/ij/
FlowJo (Facs data analysis) FlowJo Software https://www.flowjo.com/
Attune Nxt (FACS data acquisition) Attune NxT Software https://www.thermofisher.com/
FusionCapt Advance Solo 7 17.02 control and analysis software
for chemiluminescence detection (used for western blot)
Vilber Lourmat http://www.vilber.de/
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200mg/ml Hygromycin were used for selection. For experiments, complete media with Doxycycline (1ng/ml for 24h) but without Blas-
ticidin and Hygromycin was used to allow exogenous SLX4 expression.
Transfections of siRNA Oligos
Cells were transfected with siRNA oligos (40nM) using RNAiMAX (13778500, ThermoFisher) in a Pen-Strep-free media for 12 hours.
After that, fresh media containing Pen-Strep and FBS was added to the cells. Cells were collected at different time points after trans-
fection, depending on the protein of interest (see below). The following oligos were used in this study:
RAD51 (24h F_1) - 50 GAC UGC CAG GAU AAA GCU U dT dT 30
RAD51 (24h; F_2) - 50 GUC CUG CAG CCU AAU GAG A dTdT 30
SLX4 (24h) - 50 GCA CAA GGG CCC AGA ACA A dT dT 30
FANCM (48h) - 50 AAG CUC AUA AAG CUC UCG GAA dT dT 30
FANCD2 (48h) - 50 CAG AGU UUG CUU CAC UCU CUA dTdT 30
XPF (48h) - 50 GUA GGA UAC UUG UGG UUG A dT dT 30
MUS81 (48h) – 50 CAG CCC UGG UGG AUG GAU A dTdT 30
Drug Treatments
For interstrand-crosslink induction, cells were incubated with DIG-TMP (5 mM, synthesized by the lab of Prof. Dr. Gilles Gasser as
described in detail in Methods S1) or TMP (30nM, Sigma) in phenol-free, FBS-free and Pen-Strep-free DMEM media for either 1h
or 30 min in the dark. Following this incubation, cells were irradiated with UVA using a UVA chamber (300mJ/cm2 or 3J/cm2) or a
UVA laser (laser power at 45%; 50ms pulses; average nominal power < 10mW; pulsewidth < 1 ns; repetition rate > 5 kHz; wavelength
355 nm; typical pulse energy > 0.5 m J). After irradiation, cells were incubated in complete media and collected at different time points
depending on the experiments. Regardless of the type of downstream experimental approach, all manipulation post DIG-TMP/TMP
treatment was carried out in the dark.
For experiments involving PARP inhibition, cells were pre-incubatedwith olaparib (S1060, 10 mM, Selleckchem) for 1hr in in phenol-
free, FBS-free and Pen-Strep-freemedia along with DIG-TMPor TMP. Cells were then irradiated with UVA and incubated in complete
media with olaparib. For experiments involving ATR inhibition (AZ20, 1 mM, Selleckchem and VE821, 1 mM, Selleckchem) and CDC7
inhibition (XL413, 10 mM, Selleckchem), ATRi and CDC7i treatment was done in combination with DIG-TMP or TMP in phenol-free,
FBS-free and Pen-Strep-free media. Cells were then irradiated with UVA (as above) and incubated in complete media with ATRi or
CDC7i or in combination.
DNA Fiber Analysis
Asynchronously growing cells were incubated with DIG-TMP (5 mM) in phenol-free, FBS-free and Pen-Strep-free DMEMmedia for 1h
in the dark. Following this incubation, cells were irradiated with UVA (3J/cm2) and labeled with 30 mM chlorodeoxyuridine (CldU,
Sigma-Aldrich), a thymidine analog, for 30min, washed twice with PBS and exposed to 250 mM IdU. The cells were quickly trypsinized
and resuspended in PBS at 2.5 3 105 cells per ml. The labeled cells were diluted 1:5 with unlabeled cells, and 2.5 mL of cells were
mixed with 7.5 mL of lysis buffer (200mMTris-HCl (pH 7.5), 50mMEDTA, 0.5% (w/v) SDS) on a glass slide. After 9min, the slides were
tilted at 15-45, and the resulting DNA spreadswere air-dried, fixed in 3:1methanol/acetic acid at 4Covernight. The next day, slides
were denatured using 2.5M HCl for 1h and then washed using PBS. Denatured fibers were then blocked using 1% BSA in PBS.
Following the blocking, fibers were incubatedwith an anti-DIG antibody (Abcam, 1:300) overnight. Next day fiberswerewashed using
0.2% Tween in PBS (PBST). Fibers were then incubated with an anti-goat antibody Alexa 647 (Life Technologies, 1:1500) for 1h at
room temperature in amoisture chamber. Fibers were thenwashed with PBST and incubated with an antibody against CldU (Abcam,
1:500) and IdU (BD Biosciences, 1:100) for 2.5h in amoisture chamber at room temperature. Fibers were then washedwith PBST and
incubated with the corresponding secondary antibodies (anti-mouse Alexa488 (Life Technologies, 1:300) and anti-rat Cy3 (Jackson
ImmunoResearch, 1:150). After washing 5x3 min in PBST, the slides were air-dried completely, mounted with 60 uL/slide Antifade
Gold (Invitrogen). Images were acquired using an Olympus IX81 fluorescence microscope equipped with a CCD camera (Orca
AG, Hamamatsu). CldU and IdU tract lengths were measured using ImageJ and the frequency of local replication patterns was
determined manually. At least 100 fibers were analyzed per condition. The Kurskal-Wallis test was used to compute the statistical
significance in prism (GraphPad Software).
Immunofluorescence
For immunofluorescence experiments cells were grown asynchronously on coverslips or in chamber slides. Pre-extraction was con-
ducted on ice for 5min using Cytoskeletal (CSK) buffer (20mM HEPES pH 7.4, 50mM NaCl, 300mM Sucrose, 3mM MgCl2, EGTA
1mM, Triton X-100 0.5%). After pre-extraction, cells were washed using PBS and fixed for 12 min at RT using 4%Paraformaldehyde.
After fixation cells were washed with PBS and permeabilized using 0.3% Triton X-100 in PBS for 10 min at RT. Cells were then incu-
bated with the a primary antibody (see list below) overnight at 4C. The next day, cells were washed with 0.1% PBST and incubated
with the corresponding secondary antibody for 1h at RT in a moisture chamber. Cells were washed with 0.1% PBST and, if indicated
in the experiment, EdU click-it Alexa 488 was performed according to the manufacturers protocol (Invitrogen). Cells were then
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washed with PBS and stained with DAPI (0.5 mg/ml in PBS). Coverslips/chamber slides were mounted with Prolong gold antifade
reagent (Life Technologies). Cells were imaged using a Lecia Microscope (model DMRB) equipped with a camera (model
DFC360). ImageJ was used to analyze the images. For EdU intensity measurements a small Region of Interest (ROI) was drawn in
the cells away from the ICL signal and the EdU intensity of ROI was measured. For gH2AX intensity measurement of the nucleus,
DAPI was used as a mask to mark the nucleus. Kurskal-Wallis test was used to compute statistical analysis in prism (GraphPad
Software).
The following antibodies were used:
Anti-DIG (Abcam, #ab420, 1:150), anti-gH2AX (EMD Millipore, #05-636, 1:600), anti-RPA pS4/S8 (Bethyl laboratories, #A300-
245A, 1:600), anti-RAD51 (Bio Academia, #70-002, 1:600), anti-mouse 647 (Life technologies, #A31571, 1:500), anti-mouse 594
(Life technologies, #A11032, 1:500), anti-rabbit 488 (Life technologies, #A11008, 1:500) and anti-rabbit Alexa 594 (Life technologies,
#A11037, 1:500).
FACS Analysis
For DAPI/EdU/gH2AX analysis by FACS, cells were cells were cultured in the presence of EdU for 30 min prior to trypsinization.
Collected cells were spun down at 500 rcf., washed once with PBS and fixed using 4% formaldehyde. After fixation cells were
washed using 1%BSA/PBS (blocking buffer). Cells were then incubated in the same blocking buffer on ice for 15mins. Subsequently,
cells were incubated with the primary antibody (anti-gH2AX (EMD Millipore, #05-636, 1:100)) in a 1% saponin buffer (1% saponin in
blocking buffer) for 2 h at RT. Next, cells were washed and stained with an anti-mouse A647 secondary antibody (Life Technologies,
#A21235, 1:100) for 30 min at room temperature. After a wash with blocking buffer, EdU click-it was performed according to man-
ufacturers protocol (Invitrogen, #C10337). Cells were then washed and incubated with DAPI (1 mg/ml) and RNase A (0.1 mg/ml) for
15 min at room temperature. Cells were analyzed using the Attune Nxt flow cytometer (Life technologies). The FlowJo software
was used to determine S-phase cells via gating using the EdU channel and 500 random cells were selected and plotted to measure
the intensity of EdU and gH2AX across different samples. The Kurskal-Wallis test was used to compute statistical analysis in prism
(GraphPad Software).
Neutral Comet Assay
The Comet assay was performed according to the manufacturers protocol (Trevigen #4250-050- ESK). The Comet assay 2 well ES
unit with starter kit was used to perform the assay. TheOpenComet plugin of ImageJwas used to analyze the images. At least 50 cells
were analyzed and plotted using prism. The Kurskal-Wallis test was used to compute statistical analysis in prism (GraphPad
Software).
Western Blotting
Intracellular protein levels were determined by western blot analysis of whole cell extracts as described in the following. Cells were
harvested by trypsinization and lysed using 2x laemmili buffer (4%SDS, 20% glycerol, 120mM Tris-HCl pH6.8). The protein concen-
tration of the whole cell lysates was calculated using the Lowry protein assay. 4%–15% Tris-glycine gels from Biorad were used to
carry out electrophoresis. 20 - 30 mg of total protein was loaded per sample and run at 160V for 1.5h. Proteins were transferred to a
Nitrocellulose membrane (Immobilon-Pmembrane, RPN303D, Fisher Scientific) via wet transfer in a buffer containing 20%methanol
and 80%1x transfer buffer (transfer buffer 10x: 25mMTris, 192mMglycine, 10%methanol) using BioRad equipment at 100V for 2hr.
After the transfer the membrane was blocked using 2% ECL (GE healthcare #RPN 418) in 0.1% TBST. The blocked membrane was
incubated with a primary antibody overnight followed by 3 times 5 min washes with 0.1%TBST. Subsequently, the membrane
was incubated with the corresponding secondary antibody for 1 hr at room temperature. Protein bands were detected using ECL
detection reagent (Advansta #K12045-D20). The membranes were imaged using Fusion Solo (Vilber smart imaging).
The following antibodies were used:
anti-CHK1pS345 (Cell Signaling Technology, #2348, 1:1000), anti-CHK1 (Santa Cruz Biotechnology Inc., sc-8408, 1:1000), anti-
RAD51 (Santa Cruz Biotechnology Inc., #sc-8349, 1:1000, anti- ZRANB3 (Bethyl laboratories, #A303-033A, 1:1000), anti-FANCM
(kindly provided by Dr. Angelos Constantinou, 1:500), anti-GAPDH (kindly provided by Dr. Alex Sartori 1:10000), anti-mouse HRP
conjugate (GE Healthcare, #NA931V, 1:2500), anti-rabbit HRP conjugate (GE Healthcare, #NA934V, 1:2500).
Electron Microscopy
The procedure was performed as recently described (Zellweger and Lopes, 2018), with minor modifications described below. Cells
were collected, resuspended in PBS and crosslinked with 4,50, 8-trimethylpsoralen (10 mg/ml final concentration), followed by irra-
diation pulses with UV 365nmmonochromatic light (UV Stratalinker 1800; Agilent Technologies). For DNA extraction, cells were lysed
(1.28M sucrose, 40mMTris-HCl [pH 7.5], 20mMMgCl2, and 4%Triton X-100; QIAGEN) and digested (800mMguanidine–HCl, 30mM
Tris–HCl [pH 8.0], 30mM EDTA [pH 8.0], 5% Tween-20, and 0.5% Triton X-100) at 50C for 2h in presence of 1mg/ml proteinase K.
The DNA was purified using chloroform/isoamylalcohol (24:1) and precipitated in 0.7 volume of isopropanol. Finally, the DNA was
washed with 70%EtOH and resuspended in 200 mL TE (Tris-EDTA) buffer. 10U of restriction enzyme (PvuII high fidelity, New England
Biolabs) were used to digest 12 mg of mammalian genomic DNA for 4-5 h. Replication intermediates enrichment was performed by
QIAGEN Plasmid Mini Kit columns. The QIAGEN-tip 20 surface tension was reduced by applying 1mLQBT buffer. The columns were
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washed and equilibratedwith 10mMTris-HCl (pH8.0), 1MNaCl, followed by 10mMTris-HCl (pH 8.0), 300mMNaCl, respectively. DNA
was then loaded onto the columns. The columns were then washed with high NaCl solution (10mM Tris-HCl [pH 8.0] and 850mM
NaCl) and eluted in caffeine solution (10mM Tris-HCl [pH8.0], 1M NaCl, and 1.8% [w/v] caffeine). To purify and concentrate the
DNA an Amicon size-exclusion column was used. DNAwas then resuspended in TE buffer. The Benzyldimethylalkylammonium chlo-
ride (BAC) method was used to spread the DNA on the water surface and then load it on carbon-coated 400-mesh copper grids.
Subsequently, DNA was coated with platinum using a High Vacuum Evaporator MED 020 (BalTec). Microscopy was performed
with a transmission electron microscope (Tecnai G2 Spirit; FEI; LaB6 filament; high tension % 120 kV) and picture acquisition
with a side mount charge-coupled device camera (2,6003 4,000 pixels; Orius 1000; Gatan). For each experimental condition at least
70 replication fork molecules were analyzed in two independent experiments (Tables S1–S4). DigitalMicrograph version 1.83.842
(Gatan) and ImageJ (National Institutes of Health) were used to process and analyze the images.
For ‘‘immuno-EM’’ (i.e., ICL labeling with gol-conjugated antibodies), cells were treated with DIG-TMP (5 mM) and UVA (3J/cm2).
DNA was extracted and enriched for replication intermediates as described above. Before spreading the DNA using BAC method,
DNAwas incubated with a gold labeled anti-DIG antibody, which was custommade by Bio-Synthesis Inc. (Lot no. MB1556-1; size of
gold beads 6nm; antibody used for conjugation was anti-DIG from abcam #ab420; 1mg/ml). The conjugated antibody was sus-
pended in a 0.01M sodium phosphate with 0.05% azide, pH 7.2 solution. The antibody (1:100) was incubated with DNA for 1 h at
37C and then crosslinked with 0.2% glutaraldehyde for 20 min at 37C. Following the incubation DNA was spread using BAC
method with 20% formamide (47671-1L-F Sigma Aldrich).
Chromosomal Breakage and Abnormalities by Metaphase Spreading
Cells were treated for 20 hwith 75 nMMMC. The compoundwaswashed off three times with 1x PBS, uponwhich cells were released
into fresh medium containing 200 ng/ml nocodazole for 16 h. Cells were harvested and swollen with 75 mM KCl for 20 min at 37C.
Swollenmitotic cells were collected and fixed withmethanol and acetic acid (3:1). The fixing step was repeated two times. Fixed cells
were dropped onto pre-hydrated glass slides and air-dried overnight. The following day, slides were mounted with Vectashield me-
dium containing DAPI. Images were acquired with a microscope (model DMRB; Leica) equipped with a camera (model DFC360 FX;
Leica) and visible chromatid breaks/ gaps were counted.
Cell Survival by Colony Formation
Cells were seeded onto 60-mm dishes at 60% confluency. Five hours later, cells were treated with TMP, DIG-TMP, MMC and or UVA
as indicated. Eight hours after the treatments, 63 103 cells were seeded in triplicates onto 60-mm dishes and allowed to recover for
7 to 10 days. Resulting colonies were fixed with 100% ice cold methanol and stained with 0.5% Crystal Violet in 100% methanol.
Numbers of colonies were counted using a cell counter plug-in for the ImageJ software.
Quantification and Statistical Analysis
For DNA fiber analysis at least 100 tracts were scored per sample. In immunofluorescence and in comet assays, a minimum of
100 and 50 cells were analyzed, respectively. Every experiment was repeated at least twice. To assess statistical significance,
the Kurskal-Wallis test was conducted using the GraphPad Prism software (**** = p < 0.0001, *** = p < 0.001, ** p < 0.01,
* = p < 0.05 and ns = not significant). Every EM experiment was repeated twice and a minimum of 70 molecules were analyzed
per sample (Tables S1–S4).
Chemical Synthesis of DIG-TMP
For details on the chemical synthesis of DIG-TMP, see Supplemental Experimental Procedures, Methods S1: ‘‘Refined synthesis of
DIG-TMP,’’ related to STAR Methods.
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